FDA Approves Second Gene Therapy for Hemophilia B

Pfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.

Related Keywords

,Pfizer ,Drug Administration ,Hemophilia Haemophilia ,Biologic Therapy ,Iologics ,Genomics Genomic Medicine ,Gene Therapy ,Hemophiliab Haemophilia B ,Hemophiliaa Haemophilia A ,Hemorrhage ,Bleeding ,Prophylaxis ,Aminotransferase ,Dust ,Liver Enzymes ,Liver Studies ,Olt ,Ransaminase ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,